Table 4 Interproximal mean Expanded Bleeding Index (EBI) at Baseline, Weeks 4, 12

Baseline

n

53

51

52

50

52

Mean

0.305

0.296

0.367

0.342

0.311

(SD)

0.1910

0.1783

0.2061

0.1756

0.1856

Week 4

N

53

51

52

50

52

LSmean (SE)

0.213 (0.0098)

0.064 (0.0100)

0.062 (0.0100)

0.139 (0.0101)

0.047 (0.0099)

Treatment groups versus B

p-value

< 0.001

< 0.001

< 0.001

< 0.001

Difference (SE)

-0.149 (0.0140)

-0.151 (0.0140)

-0.074 (0.0141)

-0.165 (0.0139)

95% CI

[-0.177, -0.122]

[-0.178, -0.123]

[-0.101, -0.046]

[-0.193, -0.138]

% reduction

70.0

70.8

34.6

77.7

Brush/Rinse groups versus BF Superiority

p-value

Difference (SE)

95% CI

% reduction

< 0.001

-0.076 (0.0143)

[-0.104, -0.047]

54.2

< 0.001

-0.077 (0.0142)

[-0.105, -0.049]

55.4

BFZ group versus BF Superiority

p-value

Difference (SE)

95% CI

% reduction

< 0.001

-0.092 (0.0142)

[-0.120, -0.064]

65.9

BFZ versus BZ

p-value

Difference (SE)

95% CI

% reduction

0.299

-0.015 (0.0141)

[-0.042, -0.013]

23.5

Week 12

n

52

50

52

50

50

LSmean (SE)

0.241 (0.0123)

0.078 (0.0126)

0.063 (0.0124)

0.165 (0.0126)

0.049 (0.0125)

Treatment groups versus B

p-value

< 0.001

< 0.001

< 0.001

< 0.001

Difference (SE)

-0.163 (0.0176)

-0.177 (0.0175)

-0.076 (0.0176)

-0.192 (0.0176)

95% CI

[-0.198, -0.129]

[-0.212, -0.143]

[-0.110, -0.041]

[-0.226, -0.157]

% reduction

67.8

73.6

31.4

79.8

BZ versus BF Non-inferiority

p-value

< 0.001

BA versus BF Non-inferiority

p-value

< 0.001

BA versus BF Superiority

p-value

Difference (SE)

95% CI

% reduction

< 0.001

-0.087 (0.0178)

[-0.122, -0.052]

53.0

BZ versus BF Superiority

p-value

Difference (SE)

95% CI

% reduction

< 0.001

-0.102 (0.0176)

[-0.141, -0.062]

61.6

BFZ versus BF Superiority

p-value

Difference (SE)

97.5% CI

% reduction

< 0.001

-0.116 (0.0178)

[-0.156, -0.076]

70.5

BFZ versus BZ Superiority

p-value

Difference (SE)

95% CI

% reduction

0.406

-0.015 (0.0176)

[-0.049, 0.020]

23.2